Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.71

+0.4%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (5036)	12/6/2001 8:32:16 AM
From: IRWIN JAMES FRANKEL	Read Replies (2) of 52153

MLNM and CORR It looks like MLNM is doing the same thing that MEDI did when it bought AVIR. It is down 5 in pre-market trading. MEDI was a lock because it was already fairly valued - IMO. This one has more risk because MLNM has run up so strongly (16-35). But a 5 point drop in MLNM represents about a $1.1B decline in market cap. Compare that to the 55 million shares of CORR at 30 or about $1.65 billion. Buying MLNM is like getting CORR thrown in for $.55B. I will likely play this one after the market opens. More later. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next